Aakash Desai, Associate Director, Phase 1 and Precision Oncology Program at UAB O’Neal Comprehensive Cancer Center, shared a post on LinkedIn about a recent article by Zhe Huang et al, published in Nature Medicine:
“LungTIME-C01: Nature Portfolio
Can the time of day you receive immunotherapy affect survival? LungTIME-C01 suggests yes—dramatically so.
Key findings:
- PFS: 11.3 vs 5.7 months (HR 0.40)
- OS: 28.0 vs 16.8 months (HR 0.42)
- No difference in immune-related adverse events
How this fits:
In treatment-naïve advanced NSCLC, administering anti-PD-1 plus chemotherapy before 3pm nearly doubled PFS and OS compared to afternoon/evening dosing. Circulating CD8+ T cells increased in the early group but declined in the late group, suggesting a circadian-immune mechanism.
What’s next:
Validation in larger, multicenter cohorts is needed. But if confirmed, this zero-cost scheduling intervention could reshape clinical practice.”
Title: Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial
Authors: Zhe Huang, Liang Zeng, Zhaohui Ruan, Qun Zeng, Huan Yan, Wenjuan Jiang, Yi Xiong, Chunhua Zhou, Haiyan Yang, Li Liu, Jiacheng Dai, Nachuan Zou, Shidong Xu, Ya Wang, Zhan Wang, Jun Deng, Xue Chen, Jing Wang, Hua Xiang, Xiaomei Li, Boris Duchemann, Guoqiang Chen, Yang Xia, Tony Mok, Christoph Scheiermann, Francis Lévi, Nong Yang, Yongchang Zhang
You can read the Full Article in Nature Medicine.
More posts featuring Aakash Desai.